To delve deeper into the effect of TLR5 agonist treatment on macrophage function, particularly the activation of T cell immune responses, we examined the co-stimulatory molecules CD40 and CD80 on macrophages from the tumor and spleen. The gene discussed is CD40; the disease is neoplasm.